Sveriges mest populära poddar
PharmaSource Podcast
VetenskapLife Science

What BioPlan's 22-Year Data Reveals About the Future of Biopharmaceutical Outsourcing

35 min•1 december 2025

"If you can't demonstrate international quality standards, nobody is going to take a chance on a million-dollar batch to save a few dollars on their manufacturing. It just won't happen."

Eric Langer is President of BioPlan Associates, where he has systematically documented the evolution of the biomanufacturing industry since the early 2000s. In the latest PharmaSource podcast episode, Eric explains why biopharmaceutical outsourcing budgets are projected to surge 11% in 2025, the cost of talent constraints, and the rise of complex modalities like cell and gene therapies. He shares critical insights from BioPlan's 22nd annual report on what manufacturers must prioritize to succeed in an increasingly competitive landscape.


Read more.

Fler avsnitt av PharmaSource Podcast

Visa alla avsnitt av PharmaSource Podcast
How the BMC Achieves Clinical-to-Commercial Quality Continuity Across Its Biologics CDMO Platform
•23 min
Digital Twins in Claude: How BioPharma Can Build Forecast and Supply Models
•30 min
Hybrid Synthesis is Redefining Peptide Manufacturing
•29 min
The Case for Strategic CDMO Partnerships Over Multi-Sourcing
•32 min
CDMO Consolidation “Inevitable” Without Business Model Shift, Warns Cell Therapy CEO
•47 min
Trump's Most-Favored-Nation Policy Is Forcing Europe's Pharma Industry to Reconsider Its Pricing Strategy
•27 min
How Europe’s Critical Medicines Act Could Reshape Generic Drug Supply Chains
•22 min
Reshoring America’s Critical Medicines: How the API Innovation Center Turns Idle Capacity Into a Drug Security Strategy
•36 min
How Radiopharmaceutical Supply Chains Win the Race Against Radioactive Decay: Insights from Daniel Rossetto, ARTBIO
•31 min
U.S. Vaccine Policy Shifts are Create a “Chilling” Effect on Global Manufacturing and Innovation
•35 min

PharmaSource Podcast med Life Science Networks finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.